Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture

Compounds of general formula 1

• wherein
• A is selected from the group GA.1 consisting of
• a C1-C3-alkylene bridge, aryl-, heteroaryl- and heterocyclyl-,
• wherein the above-mentioned members of the group GA.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, R14—O—C1-6-alkyl-, C1-6-alkyl-, C1-6-alkyl-O—, F3C—O—, HF2C—O—, FH2C—O—, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2N—CO—,
• R1 is selected from the group GR1.1 consisting of
• H—, HO—, methyl-, ethyl-, F3C—, F3C—CH2—, H3C—O—, H3C—CH2—O—, H3C—C(O)—, (CH3)3C—O—C(O)— and HC(O)—,
• R2 is selected from the group GR2.1 consisting of
• H—, fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, F3C—O—, HF2C—O—, FH2C—O—, C1-6-alkyl-, C1-6-alkyl-S—, C1-6-alkyl-S—C1-3-alkyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-6-alkyl-, aryl-, aryl-C1-6-alkyl-, heterocyclyl-, heterocyclyl-C1-6-alkyl-, heteroaryl-, heteroaryl-C1-6-alkyl-, R14—O—, R14—O—C1-3-alkyl, (R13)2N—, (R13)2N—CO—, R13—CO—(R13)N—, (R13)2N—CO—(R13)N—, R13—SO2—(R13)N—, (R13)2N—SO2— and R13—SO2—,
• wherein the above-mentioned members of the group GR2.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, HO—C1-6-alkyl-, C1-6-alkyl-, C1-6-alkyl-O—, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2N—O—,
• R3 is selected from the group GR3.1 consisting of
• H—, fluorine, chlorine, bromine, HO—, NC—, F3C—, HF2C—, FH2C—, F3C—CH2—, F3C—O—, HF2C—O—, FH2C—O—, C1-6-alkyl-, C1-6-alkyl-S—, C2-C6-alkenyl, C1-6-alkyl-S—C1-3-alkyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-6-alkyl-, aryl-, aryl-C1-6-alkyl-, heterocyclyl-, heterocyclyl-C1-6-alkyl-, heteroaryl-, heteroaryl-C1-6-alkyl-, R12—O—, R12—O—C1-3-alkyl-, R12—S—, R12—CO—, (R13)2N—, (R13)2N—CO—, R13—CO—(R13)N—, (R13)2N—CO—(R13)N—, R13—SO2—(R13)N—, (R13)2N—SO2— and R13—SO2—,
• wherein the above-mentioned members of the group GR3.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, R14—O—, R14—O—C1-6-alkyl-, C1-6-alkyl-, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2N—CO—,
• R4 is selected from the group GR4.1 consisting of
• H—, fluorine, NC—, F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl-, C2-C6-alkenyl, C1-6-alkyl-S—, C1-6-alkyl-S—C1-3-alkyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-6-alkyl-, aryl-, aryl-C1-6-alkyl-, heterocyclyl-, heterocyclyl-C1-6-alkyl-, heteroaryl-, heteroaryl-C1-6-alkyl-, R14—O—, and R14—O—C1-3-alkyl-,
• wherein the above-mentioned members of the group GR4.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, HO—C1-6-alkyl-, C1-6-alkyl-, C1-6-alkyl-O—, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2N—CO—,
• R5 is selected from the group GR5.1 consisting of
• R6, R7—N—CO—, R8—CO—(R9)N—, and R10R11N—CO—(R9)N—,
• R6, R7 are selected from the group GR6/11.1 consisting of
• R8, R9 H—, F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl-, C2-C6-alkenyl, C1-6- alkyl-S-C1-3-
• R10, R11 alkyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-6-alkyl-, aryl-, aryl-C1-6-alkyl-, heterocyclyl-, heterocyclyl-C1-6-alkyl-, heteroaryl-, heteroaryl-C1-6-alkyl-, and R14—O—C1-3-alkyl-,
• wherein, if R6 and R7 or R10 and R11 are C1-6-alkyl groups, those two C1-6-alkyl groups bound to the same nitrogen atom of R5 may be joined together forming, together with the nitrogen atom to which they are bound, a 3 to 7 membered heterocyclic ring, and wherein one of the —CH2-groups of the heterocyclic ring formed by the R6 and R7 or R10 and R11 C1-6-alkyl groups and the nitrogen atom of R5 may be replaced by —O—, —S—, N—H, —N(C3-6-cycloalkyl)-, —N(C3-6-cycloalkyl-C1-4-alkyl)- or —N(C1-4-alkyl)- and
• wherein the above-mentioned members of the group GR6/11.1 including the the heterocyclic ring formed by the R6 and R7 or R10 and R11 C1-6-alkyl groups and the nitrogen atom of R5 may optionally be substituted independently of one another by one or more substituents selected from group GR6/11.S1 consisting of fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, HO—C1-6-alkyl-, C1-6-alkyl-, C1-6-al yl-O—, aryl-, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2—N—CO—
• wherein the above-mentioned aryl of group GR6/11.S1 may optionally be substituted independently of one another by one or more substituents selected from group consisting of
• fluorine, chlorine, bromine, NC—, F3C—, HF2C—, FH2C—, F3C—CH2—, HO—C1-6-alkyl-, C1-6-alkyl-, and C1-6-alkyl-O—,
• R12 is selected from the group GR12.1 consisting of
• F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl-, C3-6-alkenyl-, C1-6-alkyl-S—C1-3-alkyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-6-alkyl-, aryl-, aryl-C1-6-alkyl-, heterocyclyl-, heterocyclyl-C1-6-alkyl-, heteroaryl-, and heteroaryl-C1-6-alkyl-,
• wherein the above-mentioned members of the group GR12.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, R14—O—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, R14—O—C1-6-alkyl-, C1-6-alkyl-, (R13)2N—, (R13)2N—C1-3-alkyl-, and (R13)2N—CO—.
• R13 is selected from the group GR13.1 consisting of
• H—, F3C—CH2—, C1-6-alkyl-, C2-6-alkenyl-, C3-7-cycloalkyl-, C3-7-cycloalkyl-C1-3-alkyl-, aryl-, aryl-C1-3-alkyl-, heterocyclyl-, heterocyclyl-C1-3-alkyl-, heteroaryl-, and heteroaryl-C1-3-alkyl-,
• wherein two C1-6-alkyl groups bound to the same nitrogen atom may be joined together forming, together with the nitrogen atom to which they are bound, a 3 to 7 membered heterocyclic ring, and wherein one of the —CH2-groups of the heterocyclic ring formed may be replaced by —O—, —S—, N—H, —N(C3-6-cycloalkyl)-, —N(C3-6-cycloalkyl-C1-4-alkyl)- or —N(C1-4-alkyl)- and
• wherein the above-mentioned members of the group GR13.1 including the the heterocyclic ring formed may optionally be substituted independently of one another by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, HO—C1-6-alkyl-, C1-6-alkyl-, and C1-6-alkyl-O—.
• R14 is selected from the group GR14.1 consisting of
• H—, F3C—, HF2C—, FH2C—, F3C—CH2—, C1-6-alkyl-, C2-6-alkenyl-, C3-7-cycloalkyl-, C3-7-cyclyoalkyl-C1-3-alkyl-, aryl-, aryl-C1-3-alkyl-, heterocyclyl-, heterocyclyl-C1-3-alkyl-, heteroaryl- and heteroaryl-C1-3-alkyl-,
• wherein the above-mentioned members of the group GR14.1 may optionally be substituted independently of one another by one or more substituents selected from the group consisting of
• fluorine, chlorine, bromine, HO—, NC—, O2N—, F3C—, HF2C—, FH2C—, F3C—CH2—, HO—C1-6-alkyl-, C1-6-alkyl-, and C1-6-alkyl-O—,
• and pharmaceutically acceptable salts thereof.